Quick Answer
Mineralys Therapeutics, Inc. reported Stockholders Equity of $646.69 million for fiscal year 2025.
Mineralys Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $646.69M | +238.1% |
| 2024 | $191.26M | -20.7% |
| 2023 | $241.15M | +561.4% |
| 2022 | -$52.27M | -128.0% |
| 2021 | -$22.93M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $576.43M | +143.3% | +83.8% |
| June 30, 2025 | $313.55M | +8.1% | -8.2% |
| March 31, 2025 | $341.56M | +4.1% | +78.6% |
| December 31, 2024 | $191.26M | -20.7% | -19.3% |
| September 30, 2024 | $236.93M | -10.3% | -18.3% |
| June 30, 2024 | $290.10M | +1.8% | -11.6% |
| March 31, 2024 | $328.05M | +10.9% | +36.0% |
| December 31, 2023 | $241.15M | +561.4% | -8.7% |
- Mineralys Therapeutics, Inc. showed an increase of +238.1% in Stockholders Equity compared to the prior fiscal year.
- Over the 2021–2025 period, Mineralys Therapeutics, Inc.’s stockholders equity has grown by 2920.9% (from -$22.93 million to $646.69 million).
- The most recent figure is from Mineralys Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: